NCT00096837View on ClinicalTrials.gov

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

Not specified

Conditions

Multiple Myeloma

Interventions

DRUG

Motexafin Gadolinium Injection

Trial Locations (1)

60611

Robert H. Lurie Comprehensive Cancer Center, Chicago

Sponsors

Lead Sponsor

Pharmacyclics LLC.

All Listed Sponsors

lead

Pharmacyclics LLC.

INDUSTRY

NCT00096837 - A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter